Vernalis announces clinical update on partnered compounds AUY922 and HSP990
14/12/2009
Vernalis plc (LSE: VER) today announces that at its 9 December 2009 Oncology and Pipeline Update, Novartis provided an update on the clinical status of two Hsp90 inhibitors (AUY922 and HSP990), which are partnered with Vernalis.
In a presentation, Novartis indicated that it expects that several compounds may reach proof of concept in 2010, including AUY922, and that HSP990 is in Phase I dose escalation studies.
More information can be found on Novartis’ website (www.novartis.com).
-- ends --
Enquiries:
| Vernalis Contacts | |
| Ian Garland, Chief Executive Officer | +44 (0) 118 989 9360 |
| David Mackney, Chief Financial Officer | |
| Brunswick Group | |
| Jon Coles | +44 (0) 20 7404 5959 |
| Justine McIlroy |
Notes to Editors
About Vernalis
Vernalis is a development stage pharmaceutical company with
significant expertise both in de novo fragment and structure-based
drug discovery and pre-clinical and clinical development. The Group
has seven product candidates in clinical development (three of
which are partnered), two programmes in pre-clinical, as well as
other competitive research programmes. Our technologies,
capabilities and products are endorsed by collaborations with
leading, global pharmaceutical companies including GSK, Biogen
Idec, Novartis, Servier, Chiesi, Menarini, and Endo.
| Product | Indication | Pre-Clinical | Phase I | Phase II | Phase III | Marketing Rights |
| Priority Programmes | ||||||
| V3381 | Neuropathic Pain | X | Worldwide | |||
| V2006 | Parkinson’s Disease | X | Biogen Idec | |||
| V85546 | Inflammatory Disease | X | Worldwide | |||
| NVP-AUY922 | Cancer | X | Novartis | |||
| NVP-HSP990 | Cancer | X | Novartis | |||
| V3381 CC | Chronic Cough | X | Worldwide | |||
| V158866 | Pain | X | Worldwide | |||
| V158411 (Chkl) | Cancer | X | Worldwide | |||
| Progress through partnering | ||||||
| V1512 | Parkinson’s Disease | X | Worldwide (excl. Italy) | |||
| V10153 | Ischaemic Stroke | X | Worldwide | |||
For further information about Vernalis, please visit www.vernalis.com
Vernalis Forward-Looking Statement
This news release may contain forward-looking statements that
reflect the Company's current expectations regarding future events
including the clinical development and regulatory clearance of the
Company's products, the Company's ability to find partners for the
development and commercialisation of its products, as well as the
Company's future capital raising activities. Forward-looking
statements involve risks and uncertainties. Actual events could
differ materially from those projected herein and depend on a
number of factors including the success of the Company's research
strategies, the applicability of the discoveries made therein, the
successful and timely completion of clinical studies, the
uncertainties related to the regulatory process, the ability of the
Company to identify and agree beneficial terms with suitable
partners for the commercialisation and/or development of its
products, as well as the achievement of expected synergies from
such transactions, the acceptance of Frova® and other products
by consumers and medical professionals, the successful integration
of completed mergers and acquisitions and achievement of expected
synergies from such transactions, and the ability of the Company to
identify and consummate suitable strategic and business combination
transactions.
